Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EDNRA | P25101 | 1/20 | 0.59 |
| ▸ | KISS1R | Q969F8 | 7/20 | 0.56 |
| ▸ | PCSK9 | Q8NBP7 | 1/20 | 0.54 |
| ▸ | GLP1R | P43220 | 4/20 | 0.54 |
| ▸ | ECE1 | P42892 | 1/20 | 0.54 |
| ▸ | MUS81 | Q96NY9 | 1/20 | 0.54 |
| ▸ | CTSB | P07858 | 1/20 | 0.54 |
| ▸ | CTSK | P43235 | 1/20 | 0.54 |
| ▸ | PTH1R | Q03431 | 3/20 | 0.54 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.53 |
| ▸ | MAGI3 | Q5TCQ9 | 1/20 | 0.52 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30130549 | 1.00 | EDNRA (0.59) | EDNRAKISS1RPCSK9GLP1RECE1 | |
| SCHEMBL30130555 | 0.95 | KISS1R (0.57) | EDNRAKISS1RPCSK9GLP1RECE1 | |
| SCHEMBL30093053 | 0.95 | KISS1R (0.56) | EDNRAKISS1RPCSK9GLP1RECE1 | |
| SCHEMBL30093075 | 0.95 | KISS1R (0.56) | EDNRAKISS1RPCSK9GLP1RECE1 | |
| SCHEMBL30130547 | 0.95 | KISS1R (0.57) | EDNRAKISS1RPCSK9GLP1RECE1 | |
| SCHEMBL30092958 | 0.95 | MAGI3 (0.54) | EDNRAKISS1RPCSK9GLP1RECE1 | |
| SCHEMBL30092998 | 0.95 | MAGI3 (0.54) | EDNRAKISS1RPCSK9GLP1RECE1 | |
| SCHEMBL30092925 | 0.95 | MAGI3 (0.54) | EDNRAKISS1RPCSK9GLP1RECE1 | |
| SCHEMBL30092943 | 0.95 | KISS1R (0.56) | EDNRAKISS1RPCSK9GLP1RECE1 | |
| SCHEMBL30130554 | 0.94 | EDNRA (0.57) | EDNRAKISS1RPCSK9GLP1RECE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230287044-A1 | NOVEL ANTIBACTERIAL PEPTIDE AND USE THEREOF | ANYGEN CO., LTD. (KR) | 2023-09-14 | — | — | US | disclosed |
| EP-4129064-A1 | NOVEL ANTIBACTERIAL PEPTIDE AND USE THEREOF | Anygen Co., Ltd. (KR) | 2023-02-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230287044-A1 | NOVEL ANTIBACTERIAL PEPTIDE AND USE THEREOF | VIP, CUTA, LNPEP | EDNRA 3344/4885KISS1R 1140/4885PCSK9 575/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.